交易 Capricor Therapeutics Inc - CAPR 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.19
• 長倉隔夜倉息調整: -0.02157%
• 短倉隔夜倉息調整: -0.00065%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 5.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 33.35
• 開倉: 33.15
• 1 年變化: 169.07%
• 日區間: 32.59 - 34.31

Capricor Therapeutics Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company advancing cell- and exosome-based therapies for cardiac and neuromuscular disorders. Its lead program, CAP-1002, is in late-stage trials for Duchenne muscular dystrophy (DMD), with potential for FDA breakthrough designation. The company also develops exosome-based platforms for RNA delivery. Capricor offers investors high-upside, development-stage exposure to regenerative medicine and orphan diseases.